MARKET

CMRX

CMRX

Chimerix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.94
-0.16
-1.98%
After Hours: 7.71 -0.23 -2.90% 18:58 01/15 EST
OPEN
8.07
PREV CLOSE
8.10
HIGH
8.12
LOW
7.75
VOLUME
555.61K
TURNOVER
--
52 WEEK HIGH
9.66
52 WEEK LOW
1.190
MARKET CAP
497.31M
P/E (TTM)
-13.9152
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11)
Benzinga · 6d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chimerix (CMRX) and Appili Therapeutics Inc Class A (APLIF)
SmarterAnalyst · 6d ago
Looking For The Best Biotech Stocks To Watch This Week? 3 Up 70%+ Last Week
Jan 11, 2021 (StockMarket.com via COMTEX) -- Are These The Top Biotech Stocks To Watch Now? 3 To Consider Biotech stocks are still amongst the top performers...
StockMarket.com · 01/11 16:40
Company News for Jan 11, 2021
Companies in the news are: CMRX, GSAT, MRUS, FFIV
Zacks · 01/11 15:29
Company News for Jan 11, 2021
Zacks.com · 01/11 12:42
H.C. Wainwright Believes Chimerix (CMRX) Still Has Room to Grow
In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Chimerix (CMRX), with a price target of $16.00. The company's
SmarterAnalyst · 01/11 11:26
DJ Chimerix Price Target Raised to $16.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 01/11 11:19
DJ Chimerix Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 01/11 11:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CMRX. Analyze the recent business situations of Chimerix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CMRX stock price target is 9.67 with a high estimate of 16.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 130
Institutional Holdings: 39.57M
% Owned: 63.18%
Shares Outstanding: 62.63M
TypeInstitutionsShares
Increased
14
1.98M
New
21
1.04M
Decreased
36
2.19M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Independent Director
Martha Demski
President/Chief Executive Officer/Director
Michelle Berrey
President/Chief Executive Officer/Director
Michael Sherman
Chief Financial Officer
Michael Andriole
Chief Executive Officer
W. Garrett Nichols
Senior Vice President/General Counsel
Michael Alrutz
Independent Director
Catherine Gilliss
Chief Accounting Officer
David Jakeman
Independent Director
Edward Greissing
Independent Director
Patrick Machado
Independent Director
Robert Meyer
Independent Director
Fred Middleton
Independent Director
C. Patrick Machado
Independent Director
Pratik Multani
Independent Director
Clarence Machado
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CMRX
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Chimerix Inc stock information, including NASDAQ:CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.